This may be an unpopular opinion, but I do not want us to uplist anytime soon. If we spike to $4+ somehow and uplist but we don't have revenue, the share price will begin to fall. When it gets under a dollar again, we will be forced to reverse split or face being delisted which would be terrible. Trust me, I got burned by that on Cel-Sci (CVM) and I'm still waiting to get out of the hole. I almost got burned on Tonix Pharmaceuticals (TNXP) but I timed some things right there and made a decent return.

Uplisting before approval or before steady revenue is not a good idea for a biotech because the FDA can always slow walk us, make us run confirmatory trials (what happened to CVM), and/or just have things end up taking longer than expected to come to market. The big boys care about earnings season and if you have no earnings, your value will drop.